Stockreport

Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF The non-GLP-1R landscape, including calcitonin receptor (CR) products, is emerging, with sales expected to surge 50-fold over the next five years. Obesity is a chronic [Read more]